Head of Investor Relations
Johnson & Johnson (JNJ)Equibles does not estimate personal net worth.
Get an email with a short summary when Becton Dickinson & Co publishes a filing, an earnings call transcript or a press release.
Get BDX alertsChris DelOrefice is recorded as CFO at Becton Dickinson & Co (BDX) and Head of Investor Relations at Johnson & Johnson (JNJ). Chris DelOrefice has spoken on 14 earnings calls across 2 companies, most recently for Johnson & Johnson on July 15, 2026. Those appearances were for Becton Dickinson & Co (BDX) and Johnson & Johnson (JNJ). Becton Dickinson & Co is classified in the Medical Instruments & Supplies industry within the Healthcare sector. Johnson & Johnson is classified in the Drug Manufacturers - General industry within the Healthcare sector. Other leadership on record at Becton Dickinson & Co includes David F. Melcher (Chairman), Thomas E. Polen (Chairman and Board Member), Patrick K. Kaltenbach (CTO) and 7 others.
“We'll be a real asset to our company as well as the investment community. We're glad you're in the role. Hello, everyone, and thank you for joining us today.”
“Exclude the impact of currency translation. 2026 sales results, 0.3%, and 3.9% oncology in 20 basis points. of our key brands, starting with multiple 1.8%, nearly 12 points to achieve sales with continued site at 14.2%, community setting at 1.2%.”
“Echoing Tom's comments, I'm truly excited about our plan to separate Biosciences and Diagnostic Solutions. It's an exciting next step in our strategy that we believe can unlock significant value for both New BD and Biosciences and Diagnostic Solutions.”
“As Tom noted, we delivered competitive organic revenue growth for the fourth quarter and full year even while navigating market dynamics in China and Bioscience-Pharma.”
“As Tom noted, the quarter's results reflect strong performance across multiple parts of our portfolio, even amid the previously noted transitory market dynamics and macro factors.”
Medical Instruments & Supplies · Healthcare
CFO
Drug Manufacturers - General · Healthcare
Head of Investor Relations
